The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer [Video]

• The positive three-year follow-up results of the PHERGain clinical trial, sponsored by MEDSIR, demonstrating that one-third of patients with localized HER2-positive breast cancer can be cured without the need for chemotherapy, have been published in the prestigious scientific journal The Lancet.
• PHERGain is the first study with a strategic design that allows tailoring therapy for each patient based on the initial treatment response and complete pathological response.
• Results indicate that 94.8% of all patients who followed this adaptive treatment strategy remain free from recurrence of their cancer after 3 years of follow-up.

JERSEY CITY, N.J., April 4, 2024 /PRNewswire/ — The PHERGain clinical trial, developed by MEDSIR – a company dedicated to promoting independent clinical research in oncology internationally – has been published in the prestigious journal The Lancet, following positive results showing that one-third of patients with localized HER2-positive breast cancer can be cured without requiring chemotherapy, drastically reducing side effects.

This study marks a milestone …